{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:39:47Z","timestamp":1779104387691,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"am","delay-in-days":191,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.braindev.2020.07.019","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T01:30:57Z","timestamp":1597109457000},"page":"214-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of bezafibrate for preventing myopathic attacks in patients with very long-chain acyl-CoA dehydrogenase deficiency"],"prefix":"10.1016","volume":"43","author":[{"given":"Hideaki","family":"Shiraishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Ishige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asami","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanae","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyo","family":"Kuzume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Sameshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyotaka","family":"Nakamagoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Tamaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Yokoshiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Miyakoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Isoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2020.07.019_b0005","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/jimd.12075","article-title":"Impact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes","volume":"42","author":"Bleeker","year":"2019","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.braindev.2020.07.019_b0010","first-page":"5","article-title":"Diversity in the incidence and spectrum of organic acidemias, fatty acid oxidation disorders, and amino acid disorders in Asian countries: selective screening vs. expanded newborn screening","volume":"16","author":"Shibata","year":"2018","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.braindev.2020.07.019_b0015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10545-009-9001-1","article-title":"Fatty acid oxidation disorders: outcome and long-term prognosis","volume":"33","author":"Wilcken","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.braindev.2020.07.019_b0020","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.physiol.64.082201.154705","article-title":"Fatty acid oxidation disorders","volume":"64","author":"Rinaldo","year":"2002","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.braindev.2020.07.019_b0025","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.braindev.2020.07.019_b0030","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0021-9150(78)90138-7","article-title":"One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia","volume":"31","author":"Olsson","year":"1978","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.braindev.2020.07.019_b0035","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0021-9150(78)90137-5","article-title":"Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinanemia","volume":"31","author":"Olsson","year":"1978","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.braindev.2020.07.019_b0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.braindev.2016.08.004","article-title":"Efficacy of bezafibrate on fibroblasts of glutaric acidemia type II patients evaluated using an in vitro probe acylcarnitine assay","volume":"39","author":"Yamada","year":"2017","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2020.07.019_b0045","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/hmg\/ddi303","article-title":"Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders","volume":"14","author":"Djouadi","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2020.07.019_b0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10545-008-0844-7","article-title":"PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders","volume":"31","author":"Djouadi","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.braindev.2020.07.019_b0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10545-015-9871-3","article-title":"Mitochondrial trifunctional protein deficiency in human cultured fibroblasts: effects of bezafibrate","volume":"39","author":"Djouadi","year":"2016","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.braindev.2020.07.019_b0060","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1056\/NEJMc0806334","article-title":"Bezafibrate for an inborn mitochondrial beta-oxidation defect","volume":"360","author":"Bonnefont","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2020.07.019_b0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/clpt.2010.55","article-title":"Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency","volume":"88","author":"Bonnefont","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.braindev.2020.07.019_b0070","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ymgme.2012.07.004","article-title":"Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: evaluation by in vitro probe acylcarnitine assay","volume":"107","author":"Yamaguchi","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.braindev.2020.07.019_b0075","first-page":"55","article-title":"Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan","volume":"15","author":"Yamada","year":"2018","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.braindev.2020.07.019_b0080","article-title":"Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan; 2nd report QOL survey","volume":"20","author":"Shiraishi","year":"2019","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.braindev.2020.07.019_b0085","first-page":"17","article-title":"Clinical course in a patient with myopathic VLCAD deficiency during pregnancy with an affected baby","volume":"49","author":"Yamada","year":"2019","journal-title":"JIMD Rep"},{"key":"10.1016\/j.braindev.2020.07.019_b0090","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/WNL.0000000000000118","article-title":"Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial","volume":"82","author":"\u00d8rngreen","year":"2014","journal-title":"Neurology"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760420302023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760420302023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:49:56Z","timestamp":1759952996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760420302023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0387760420302023"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2020.07.019","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of bezafibrate for preventing myopathic attacks in patients with very long-chain acyl-CoA dehydrogenase deficiency","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2020.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}